Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C29H28N2O7 |
| Molecular Weight | 516.5418 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(OC(=O)N(CC(O)=O)CC2=CC=C(OCCC3=C(C)OC(=N3)C4=CC=CC=C4)C=C2)C=C1
InChI
InChIKey=IRLWJILLXJGJTD-UHFFFAOYSA-N
InChI=1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33)
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17062777 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
MURAGLITAZAR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
12 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17062777 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
MURAGLITAZAR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
35.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17062777 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
MURAGLITAZAR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. | 2014-04-01 |
|
| Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes. | 2011-07-01 |
|
| Successful drug development despite adverse preclinical findings part 2: examples. | 2010-12 |
|
| A PPARα promoter variant impairs ERR-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetes. | 2010-09-03 |
|
| Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. | 2010-05-01 |
|
| Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. | 2010-02 |
|
| Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver. | 2010 |
|
| Peroxisome proliferator-activated receptor (PPAR): balance for survival in parasitic infections. | 2010 |
|
| Improving access to FDA reviews and documents. | 2009-11-25 |
|
| A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. | 2009-07-20 |
|
| PPAR-alpha and PPAR-gamma agonists for type 2 diabetes. | 2009-07-11 |
|
| Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes. | 2009-07 |
|
| Coadministration of muraglitazar plus glyburide: improvement of glycaemic and lipid profiles in patients with type 2 diabetes. | 2009-04 |
|
| Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy sprague-dawley rats. | 2009 |
|
| Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. | 2008-12-15 |
|
| Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists. | 2008-10-23 |
|
| Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists. | 2008-10 |
|
| Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride. | 2008-09 |
|
| Therapy for nonalcoholic fatty liver disease. | 2008-04 |
|
| Rapid and sensitive characterization of the metabolite formation enzyme kinetics of radiolabeled drugs using stop-flow liquid radiochromatography. | 2008-01 |
|
| Development of Synthetic Modulators of PPARs: Current Challenges and Future Opportunities. | 2008 |
|
| PPARgamma in Kidney Physiology and Pathophysiology. | 2008 |
|
| Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists. | 2008 |
|
| Renal and vascular mechanisms of thiazolidinedione-induced fluid retention. | 2008 |
|
| The Development of INT131 as a Selective PPARgamma Modulator: Approach to a Safer Insulin Sensitizer. | 2008 |
|
| Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. | 2008 |
|
| PPAR-gamma, Microglial Cells, and Ocular Inflammation: New Venues for Potential Therapeutic Approaches. | 2008 |
|
| Should We Use PPAR Agonists to Reduce Cardiovascular Risk? | 2008 |
|
| PPAR Agonists and Cardiovascular Disease in Diabetes. | 2008 |
|
| Optimization to eliminate the interference of migration isomers for measuring 1-O-beta-acyl glucuronide without extensive chromatographic separation. | 2008 |
|
| Mass defect filtering on high resolution LC/MS data as a methodology for detecting metabolites with unpredictable structures: identification of oxazole-ring opened metabolites of muraglitazar. | 2007-12 |
|
| Accessing FDA approval packages and briefing documents. | 2007-12 |
|
| Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. | 2007-12 |
|
| Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist. | 2007-11 |
|
| Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urothelium. | 2007-09-15 |
|
| PPAR dual agonists: are they opening Pandora's Box? | 2007-08 |
|
| Design, synthesis, and structure-activity relationship of carbamate-tethered aryl propanoic acids as novel PPARalpha/gamma dual agonists. | 2007-07-01 |
|
| Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar. | 2007-07 |
|
| The integration of lipid-sensing and anti-inflammatory effects: how the PPARs play a role in metabolic balance. | 2007-05-25 |
|
| The dual peroxisome proliferator-activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice. | 2007-04 |
|
| Subchronic urinary bladder effects of muraglitazar in male rats. | 2007-03 |
|
| Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema? | 2007-02 |
|
| Assessment of dose proportionality of muraglitazar after repeated oral dosing in rats via a sparse sampling methodology. | 2007-01 |
|
| Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. | 2007-01 |
|
| Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. | 2007-01 |
|
| Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes. | 2007 |
|
| Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys. | 2006-12 |
|
| A bumpy road to breakthroughs. The news: it's hard to beat today's cardiac treatments. | 2006-02 |
|
| K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome. | 2006 |
|
| Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action. | 2006 |
Sample Use Guides
This was a randomized, double-blind, placebo-controlled, parallel-group, multicenter, 24-week monotherapy study in drug-naive, type 2 diabetes patients with inadequate glycemic control. Men and women aged 18 to 70 years with a body mass index < or =41 kg/m(2) and serum triglyceride levels < or =600 mg/dL were eligible for study participation. The study included double-blind and open-label treatment phases. Patients with glycosylated hemoglobin (HbA(1c)) levels > or =7.0% and < or =10.0% at screening were enrolled in the double-blind treatment phase. These patients received treatment with muraglitazar 2.5 mg, muraglitazar 5 mg, or placebo.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C98233
Created by
admin on Mon Mar 31 18:12:03 GMT 2025 , Edited by admin on Mon Mar 31 18:12:03 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB21507
Created by
admin on Mon Mar 31 18:12:03 GMT 2025 , Edited by admin on Mon Mar 31 18:12:03 GMT 2025
|
PRIMARY | |||
|
W1MKM70WQI
Created by
admin on Mon Mar 31 18:12:03 GMT 2025 , Edited by admin on Mon Mar 31 18:12:03 GMT 2025
|
PRIMARY | |||
|
CHEMBL186179
Created by
admin on Mon Mar 31 18:12:03 GMT 2025 , Edited by admin on Mon Mar 31 18:12:03 GMT 2025
|
PRIMARY | |||
|
8442
Created by
admin on Mon Mar 31 18:12:03 GMT 2025 , Edited by admin on Mon Mar 31 18:12:03 GMT 2025
|
PRIMARY | |||
|
PP-02
Created by
admin on Mon Mar 31 18:12:03 GMT 2025 , Edited by admin on Mon Mar 31 18:12:03 GMT 2025
|
PRIMARY | |||
|
MURAGLITAZAR
Created by
admin on Mon Mar 31 18:12:03 GMT 2025 , Edited by admin on Mon Mar 31 18:12:03 GMT 2025
|
PRIMARY | |||
|
331741-94-7
Created by
admin on Mon Mar 31 18:12:03 GMT 2025 , Edited by admin on Mon Mar 31 18:12:03 GMT 2025
|
PRIMARY | |||
|
DB06510
Created by
admin on Mon Mar 31 18:12:03 GMT 2025 , Edited by admin on Mon Mar 31 18:12:03 GMT 2025
|
PRIMARY | |||
|
100000088312
Created by
admin on Mon Mar 31 18:12:03 GMT 2025 , Edited by admin on Mon Mar 31 18:12:03 GMT 2025
|
PRIMARY | |||
|
DTXSID9057719
Created by
admin on Mon Mar 31 18:12:03 GMT 2025 , Edited by admin on Mon Mar 31 18:12:03 GMT 2025
|
PRIMARY | |||
|
206044
Created by
admin on Mon Mar 31 18:12:03 GMT 2025 , Edited by admin on Mon Mar 31 18:12:03 GMT 2025
|
PRIMARY | |||
|
m1210
Created by
admin on Mon Mar 31 18:12:03 GMT 2025 , Edited by admin on Mon Mar 31 18:12:03 GMT 2025
|
PRIMARY | Merck Index | ||
|
C75190
Created by
admin on Mon Mar 31 18:12:03 GMT 2025 , Edited by admin on Mon Mar 31 18:12:03 GMT 2025
|
PRIMARY | |||
|
C500085
Created by
admin on Mon Mar 31 18:12:03 GMT 2025 , Edited by admin on Mon Mar 31 18:12:03 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
